Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
01/09/2026 11:26
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate Sept 1 (Reuters) - Chinese drugmaker Simcere Pharmaceutical signed a licensing agreement with Roche on Monday, granting the Swiss pharmaceutical company exclusive global rights to develop, manufacture and commercialise SIM0660, an antibody targeting B-cell cancers.
As per deal terms, Simcere is eligible to receive $75 million of upfront payment and up to $1.46 billion in milestone payments.
(Reporting by Jasmeen Ara Shaikh in Bengaluru; Editing by Anil D'Silva)
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660